Skip to content Skip to footer
Subscribe Now
PharmaShots Interview In Conversation with Amolyt’s CEO, Thierry Abribat, Where he Shares Insights on Amolyt as a Key Player in Hypoparathyroidism Space
VIEWPOINTS

PharmaShots Interview: In Conversation with Amolyt’s CEO, Thierry Abribat, Where he Shares Insights on Amolyt as a Key Player in Hypoparathyroidism Space

Shots: Thierry spoke about the IND clearance of its lead candidate in hypoparathyroidism and the company’s clinical trial plans for rare endocrine and related diseases Thierry also communicated about the closing of funding Series B equity financing round The interview gives a deeper understanding of Hypoparathyroidism and its treatment options Smriti: What did this Investigational…
June 1, 2022

Read more

PharmaShots Interview In Conversation with Pyxis’ CMO Jay M. Feingold, Where he Shares Insights on the addition of In-Licensed & Internal IO Assets
VIEWPOINTS

PharmaShots Interview: In Conversation with Pyxis’ CMO Jay M. Feingold, Where he Shares Insights on the addition of In-Licensed & Internal IO Assets

Shots: Jay talked about the in-licensing of an IND-ready immuno-oncology (IO) candidate, anti-Siglec-15 Mab to the pipeline Jay also spoke about the company’s IO targets and other under development immunotherapies In addition, the interview provided the corporate and financial updates of the Pyxis Oncology Smriti: Can you tell us something about your in-licensed Mab anti-Siglec-15,…
May 31, 2022

Read more

PharmaShots Interview MindMed’s Robert Barrow Shares Insights on Study to show Key Differences Between LSD and Psilocybin
VIEWPOINTS

PharmaShots Interview: MindMed’s Robert Barrow Shares Insights on Study to show Key Differences Between LSD and Psilocybin

In an interview with PharmaShots, Robert Barrow, CEO at MindMed shared his views on the Study Acute Effects of Lysergic Acid Diethylamide vs. Psilocybin in Healthy Subjects Shots: Robert spoke about the data from the peer-reviewed publication of a study comparing the acute effects of LSD and psilocybin in healthy subjects Robert also emphasized the clinical results and significance of…
May 30, 2022

Read more

PharmaShots Interview Medicago’s Brian Ward Shares Insights on COVIFENZ, a Plant-Based COVID-19 Vaccine
VIEWPOINTS

PharmaShots Interview: Medicago’s Brian Ward Shares Insights on COVIFENZ, a Plant-Based COVID-19 Vaccine

In an interview with PharmaShots, Brian Ward, CEO at Medicago shared his views on the approval of a Plant-Based COVID-19 Vaccine in combination with GSK’s pandemic adjuvant Shots: Brian talked about the data that supported the approval of Medicago’s plant-based Covid-19 vaccine by Health Canada He focused on the safety and efficacy of the vaccine…
May 25, 2022

Read more

PharmaShots Interview Biogen’s Monica Mann Shares Insights on the New Real-World Data on Tysabri & Vumerity for the Treatment of Multiple Sclerosis
VIEWPOINTS

PharmaShots Interview: Biogen’s Monica Mann Shares Insights on the New Real-World Data on Tysabri & Vumerity for the Treatment of Multiple Sclerosis

In an interview with PharmaShots, Monica Mann, Vice President, Medical Affairs for Global MS and Pipeline at Biogen shared her views on the data of Tysabri, Vumerity & highlights of new digital health research to predict multiple sclerosis disease progression Shots: Monica spoke about detailed results of the new real-world & clinical data on the long-term use of Tysabri & real-world analyses…
May 17, 2022

Read more

Exclusive_Anita Holz1_Alanna Morris2-2022
EXCLUSIVE

Exclusive Interview with PharmaShots: Anita Holz of Boehringer Ingelheim And Alanna Morris of Emory University Share Insight on Hear Your Heart

In an interview with PharmaShots, Anita Holz, MSN, CRNP, Therapeutic Area Head, Cardiometabolism Medical Affairs, Boehringer Ingelheim & Alanna Morris, Associate Professor of Medicine, Division of Cardiology, Emory University School of Medicine shared their views on the launch of Hear Your Heart to provide resources and education for women with heart failure & highlight inequitable care in black and Latina women Shots: Boehringer &…
May 16, 2022

Read more

PharmaShots Interview GSK’ Angela Carroll Shares Insights on First Paper to Define Disease Modification in Systemic Lupus Erythematosus
VIEWPOINTS

PharmaShots Interview: GSK’ Angela Carroll Shares Insights on First Paper to Define Disease Modification in Systemic Lupus Erythematosus

In an interview with PharmaShots, Angela Carroll, US Medical Affairs Scientific Director-Immuno-inflammation at GSK shared her views on a first published article on disease modification in systemic lupus erythematosus, published in Lupus Science & Medicine Shots: The company has published the first research to define disease modification in SLE including LN in the Lupus Science & Medicine. In multiple therapeutic…
May 11, 2022

Read more

Load more